Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
about
Radiotherapy combination opportunities leveraging immunity for the next oncology practiceIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsTargeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesIdentification and characterization of HPV-independent cervical cancers.Are peptide vaccines viable in combination with other cancer immunotherapies?Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.Current state in the development of candidate therapeutic HPV vaccinesDNA-based immunotherapy for HPV-associated head and neck cancer.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice.TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.A facile approach to enhance antigen response for personalized cancer vaccination.CD137-CRDI is not necessary in the role of contacting its natural ligand.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.
P2860
Q26738443-5117C784-72A3-42BB-A85B-30FD3067246AQ28072532-B52A48E8-4049-4E07-9A0C-698911C694EAQ37494787-0DDEBF8B-3FF3-415A-95EF-C90C317561A8Q37706624-9BEDC098-8DB2-4C79-8EBB-8A8550C17167Q38646990-C2FB7196-5791-4698-BF28-28D75693CE85Q38698632-13B5CDA4-250F-4F6D-BE37-4045CF14AA1DQ38706874-AE0C948F-25F0-4749-9BE8-449A2683706FQ38743922-08FE2708-DF63-401B-85F0-B269D3900400Q38948889-1833B0E4-BD8E-4FE5-AE9E-0F0F517450F5Q39189908-DF3DD604-F07B-4C9E-A34E-AFCC7350637CQ40500189-5FEF3E46-DE47-4273-9CD2-6B62C2C847D8Q45064262-6C1BA45D-2F7E-4EFB-AC11-49D7DBB69D41Q47098614-CA30095F-6B5C-4179-9DA0-89A927D4A6ACQ49715023-ED962272-5134-4895-9107-1CB4E2258BF5Q50115667-121DBBBF-9A7B-494A-BAFA-B557539F86EDQ50532509-A74D72C5-0D04-44D3-A679-13A207CE2B52Q50783362-F0F20654-6CB9-4FD6-88C3-75BA2CA5DCC7Q52683991-B56A75F5-6CD4-4177-B9AB-CE3C00FD7D7FQ55163909-380B29C7-AD8E-4D36-9CCC-922A05650ED1
P2860
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine.
@ast
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine.
@en
type
label
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine.
@ast
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine.
@en
prefLabel
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine.
@ast
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine.
@en
P2093
P2860
P50
P356
P1476
Unique potential of 4-1BB agon ...... with an E6/E7 peptide vaccine
@en
P2093
Dhwani Haria
Guojun Yang
Shailbala Singh
P2860
P304
P356
10.1073/PNAS.1514418112
P407
P577
2015-09-08T00:00:00Z